Iron Chelation Therapy With Deferasirox in Sickle Cell Disease With End-Stage Renal Disease

Patients with transfusion‐dependent sickle cell disease (SCD) are at risk of iron overload and its complications. Iron overload is a significant risk factor for chronic liver disease in patients who are dependent on hemodialysis secondary to end-stage renal disease (ESRD). Deferasirox is being incre...

Descripción completa

Detalles Bibliográficos
Autores principales: Raj, Ashok, McGowan, Kerry, Knapp, Esther, Zhao, Jun, Shah, Siddharth
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2022
Materias:
Nephrology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9107315/
https://www.ncbi.nlm.nih.gov/pubmed/35582552
http://dx.doi.org/10.7759/cureus.24146

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9107315/
https://www.ncbi.nlm.nih.gov/pubmed/35582552
http://dx.doi.org/10.7759/cureus.24146

Ejemplares similares